Important Disclaimer: Ken Kam, Marketocracy Data Research's Editor in Chief, also is portfolio manager for mutual and hedge funds advised by a Marketocracy affiliate. Before relying on his opinions, always assume that he, Marketocracy, its affiliates and clients have material financial interests in these stocks and hold or trade them contrary to those opinions. Continue reading for more detailed and important disclosures, disclaimers, limitations and material conflicts of interest.
Ken Kam
![[Ken Kam]](/images/ken.jpg)
Sections
October 26, 2007
Elan: Listening to Patients
If you have had to make the decision about whether to use Tysabri, I would love to hear from you. Click on the "Comment" button to tell me your story.
Continue reading "Elan: Listening to Patients" »
Read more posts from the ELN journal
Top Posts for 'ELN' from Strategy Lab Open
| Rating | Title | |
|---|---|---|
| -0.77 | (26 votes) | 2nd weekly review, by hey4qt |
More posts on ELN from Marketocracy Strategy Lab Open
Top Posts for 'ELN' from Marketocracy Forums
| Rating | Title | |
|---|---|---|
| 3.00 | (63 votes) | Being a fundamentalist, and admittedly biased as such,, by jurac |
| 3.00 | (42 votes) | I am a neurologist, also in Biotech. I have to say, by djacoby |
| 3.00 | (30 votes) | Re:Elan: Listening to Patients, by msladyinca |
| 3.00 | (20 votes) | In my opinion Tysabri will be back as mono therapy., by cliveg |
| 3.00 | (20 votes) | Elan?s decision to move bapineuzumab, AAB-001, to, by cliveg |
![[marketocracy]](/images/mlogo_footer.gif){kind=small}
Marketocracy
Rules | Privacy
Statement | Services
Agreement | Questions